A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer
NCT ID: NCT00563095
Last Updated: 2010-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2004-03-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary: To compare the side effects of TACE and TAIE.
The outcome measurements include survival benefit and tumour regression induced by the two therapies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NCT06487663
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
NCT04997850
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
NCT00493402
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
NCT02070419
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
NCT02631499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcatheter Arterial Chemoembolization (TACE)
Transcatheter Arterial Pegylated Interferon Embolization (TAIE)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Severe arteriovenous shunt
* Bilirubin level \> 50 umol/mL
* Prothrombin time \> 5 seconds
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schering-Plough
INDUSTRY
Hospital Authority, Hong Kong
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Man Fung Yuen, Prof
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HARECCTR0500039
Identifier Type: -
Identifier Source: secondary_id
EC 1942-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.